News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: China To Add 300 Drugs To National Reimbursement Drug List
According to sources, China is getting close to announcing a revised National Reimbursement Drug List, the group of drugs covered by China's national insurance plan. 130 will be chemical drugs and the rest will be traditional Chinese medicines.
Read
Week In Review: China Investors Announce $4 Billion Of Life Science Deals
Temasek, the sovereign wealth fund of Singapore, invested $800 million in Verily Life Sciences LLC of San Francisco (see story). Verily is the former health sciences division of Google's R&D operations, now spun out into a separate company.
Read
Week In Review: WuXi AppTec Acquires HD Biosciences In China CRO Tieup
New Century Healthcare, a Beijing operator of children's clinics/hospitals and a recently acquired women's hospital, completed a $114 million IPO in Hong Kong. The transaction was priced at the middle of the expected range.
Read
Week In Review: China's Sanpower Pays $820M For Provenge, A Prostate Immunotherapy
Sanpower Group, a China conglomerate, paid $820 million to acquire Dendreon, which makes Provenge, the world's first immunotherapy, from Valeant Pharma.
Read
Week In Review: ICarbonX "Ecosystem" Invests $400 Million In Seven Companies
Following is this week's news in Chinese biopharma. The biggest news - iCarbonX, the Shenzhen big data/artificial intelligence health company, formed The Digital Life Alliance with seven outside life science companies.
Read
Week In Review: China's New Century Healthcare Plans Hong Kong IPO
New Century Healthcare, which operates three pediatric clinics and recently acquired a women's hospital, all in Beijing, was approved to stage a $100 million IPO on the Hong Kong exchange. It's expected to take place in January 2017.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

LATEST ACTIVITY

ChinaBio® Today
Week In Review: China To Add 300 Drugs To National Reimbursement Drug List $AZN $AZN $GSK $FGEN https://t.co/0aWI2r4kI5 less
ChinaBio® Today
Week in Review: #China Investors Announce $4 Billion of Life Science Deals $CO...

more
ChinaBio® Today
RT BioPharmaJosh: 1 to watch: Chinese regulators tightening Rx distribution chain https://t.co/dNW3A7OYPV...

more
All Posts

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications